Rhesus blood group system

Rhesus blood group system
Anvesha456 · CC BY-SA 4.0 · source
Name	Rhesus blood group system
Antigen type	Protein (Rh)
Genes	RHD, RHCE
Clinical significance	Hemolytic disease of the fetus and newborn; transfusion reactions

Contents

Rhesus blood group system The Rhesus blood group system is a major human blood group characterized by immunogenic protein antigens on erythrocyte membranes that are clinically important in transfusion and perinatal medicine. Identified through serologic work in the early 20th century, its primary antigens arise from the RHD and RHCE genes on chromosome 1 and interact with immune responses relevant to World Health Organization, American Red Cross, Royal College of Pathologists, Centers for Disease Control and Prevention, and European Directorate for the Quality of Medicines guidelines. Research into its molecular structure and population genetics has involved laboratories at Cambridge University, Harvard Medical School, University of Oxford, Max Planck Society, and institutes associated with National Institutes of Health.

Overview

The system includes multiple antigens—most notably the D antigen—encoded by allelic variations of RHD and RHCE, discovered after serologic incompatibilities reported in clinical series at Rockefeller Institute and described in reports linked to investigators at Columbia University, Johns Hopkins University, and Mayo Clinic. Phenotypes commonly referenced in transfusion practice include D-positive and D-negative status, terms used in protocols by World Health Organization and national blood services such as NHS Blood and Transplant and Australian Red Cross Lifeblood. The practical classification affects practices in United Kingdom National Health Service, United States Food and Drug Administration, European Medicines Agency, and hospital transfusion committees.

The genes RHD and RHCE are located on chromosome 1 and form a complex locus with copy-number variation, gene conversion, and hybrid alleles; molecular characterization has been advanced by groups at Cold Spring Harbor Laboratory, Sanger Institute, Broad Institute, Karolinska Institutet, and University of Tokyo. The RHD gene encodes the D antigen protein; complete deletions, nonsense mutations, and frameshifts produce D-negative phenotypes observed in populations studied by teams at University of Cape Town, Institut Pasteur, Max Planck Institute for Evolutionary Anthropology, and Chinese Academy of Medical Sciences. RHCE encodes C, c, E, and e antigens via alternative alleles; clinicians and researchers from Stanford University, Yale School of Medicine, Mount Sinai Hospital, and University of Toronto have described allelic variants and amino-acid substitutions that alter serologic reactivity. Molecular assays developed at Molecular Diagnostics Laboratorys and commercial firms in coordination with regulators such as European Directorate for the Quality of Medicines detect single-nucleotide polymorphisms, hybrid genes, and regulatory changes.

Serologic methods using monoclonal and polyclonal antisera remain standard in blood centers like American Red Cross, NHS Blood and Transplant, and Canadian Blood Services; automated platforms and gel column techniques were standardized through work at Grifols, Ortho Clinical Diagnostics, Bio-Rad Laboratories, and academic transfusion services at University College London Hospitals. Molecular typing employs PCR-SSP, PCR-RFLP, and next-generation sequencing workflows validated by consortia at European Society for Blood and Marrow Transplantation, International Society of Blood Transfusion, and national reference labs in Germany, France, Japan, and Brazil. Specialized testing for weak D and partial D variants—important in obstetric and transfusion decision-making—was refined in studies at Massachusetts General Hospital, Karolinska University Hospital, University of Amsterdam, and Hospital Clínic de Barcelona.

D incompatibility is a major cause of acute and delayed hemolytic transfusion reactions documented in case series from Johns Hopkins Hospital, Cleveland Clinic, Mayo Clinic, and multicenter registries coordinated by Food and Drug Administration surveillance and European Hematology Association. Transfusion protocols incorporate Rh typing, crossmatching, and antibody screening guided by policies from American Association of Blood Banks, NHS Blood and Transplant, and country-specific blood services including Japan Red Cross Society and South African National Blood Service. Management of alloimmunized patients involves antigen-matched blood procurement, erythrocytapheresis practices at specialty centers like Karolinska University Hospital and use of immunomodulation strategies evaluated in trials at Imperial College London and Vanderbilt University Medical Center.

Maternal anti-D alloimmunization, first characterized in obstetric reports and epidemiologic studies from University of Edinburgh, University of Glasgow, Beth Israel Deaconess Medical Center, and Leiden University Medical Center, can cause hemolytic disease of the fetus and newborn (HDFN) with outcomes ranging from fetal anemia to hydrops fetalis managed by fetal transfusion programs at Great Ormond Street Hospital, St Thomas' Hospital, and fetal medicine centers at University College London Hospitals. Prophylaxis with anti-D immunoglobulin—developed through collaborations involving Rhesus prophylaxis research groups, plasma fractionation by firms such as CSL Limited and implemented by national programs in United Kingdom, Australia, and New Zealand—has dramatically reduced alloimmunization rates; guidelines are promulgated by organizations like Royal College of Obstetricians and Gynaecologists and American College of Obstetricians and Gynecologists. Contemporary management involves noninvasive cell-free fetal DNA assays pioneered at Sana Biotechnology-adjacent labs and diagnostic services at Sequenom-affiliated centers.

Distribution of D-positive and D-negative alleles varies geographically and ethnically, with high D-negative frequencies in populations studied in Northern Europe, lower frequencies in cohorts from Sub-Saharan Africa, East Asia, and admixture patterns documented by population geneticists at Harvard University, University of California, Berkeley, University of São Paulo, and University of Cape Town. Evolutionary hypotheses addressing selective pressures, founder effects, and balancing selection have been examined using data from projects at 1000 Genomes Project, Human Genome Project, HapMap Project, and analyses by researchers at Max Planck Institute for Evolutionary Anthropology and Wellcome Sanger Institute. Anthropological and forensic applications of Rh typing were historically used in studies by institutions such as Smithsonian Institution and British Museum, while modern genomic analyses integrate RH variation into broader studies of human migration and admixture coordinated by international consortia.

Category:Blood antigen systems